304 related articles for article (PubMed ID: 32527699)
21. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Sommerstein R; Kochen MM; Messerli FH; Gräni C
J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
[No Abstract] [Full Text] [Related]
22. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
[No Abstract] [Full Text] [Related]
23. COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure.
Siniorakis E; Arvanitakis S; Nikolopoulos I; Elkouris M
mBio; 2020 May; 11(3):. PubMed ID: 32444383
[No Abstract] [Full Text] [Related]
24. What would Sérgio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?
Nicolau LAD; Magalhães PJC; Vale ML
Med Hypotheses; 2020 Oct; 143():109886. PubMed ID: 32504925
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors.
Milne S; Yang CX; Timens W; Bossé Y; Sin DD
Lancet Respir Med; 2020 Jun; 8(6):e50-e51. PubMed ID: 32411576
[No Abstract] [Full Text] [Related]
26. Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
[TBL] [Abstract][Full Text] [Related]
27. Renin-Angiotensin-Aldosterone Inhibitors and COVID-19 Infection.
Tsampasian V; Corballis N; Vassiliou VS
Curr Hypertens Rep; 2022 Oct; 24(10):425-433. PubMed ID: 35716247
[TBL] [Abstract][Full Text] [Related]
28. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
30. Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension.
Cure E; Cumhur Cure M; Vatansev H
J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972015. PubMed ID: 33169637
[No Abstract] [Full Text] [Related]
31. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
Esler M; Esler D
J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
[No Abstract] [Full Text] [Related]
32. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Sadria M; Layton AT
PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
34. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
Zhang J; Wang M; Ding W; Wan J
Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 and the cardiovascular system.
Zheng YY; Ma YT; Zhang JY; Xie X
Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 Pathogenesis: Imbalance in the Renin-Angiotensin System Favors Lung Fibrosis.
Delpino MV; Quarleri J
Front Cell Infect Microbiol; 2020; 10():340. PubMed ID: 32596170
[No Abstract] [Full Text] [Related]
37. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
38. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
[TBL] [Abstract][Full Text] [Related]
39. COVID-19: The heart of the issue.
Woodward B; Kermali M
J Card Surg; 2020 Aug; 35(8):2112. PubMed ID: 32542802
[No Abstract] [Full Text] [Related]
40. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]